跳至主要内容
临床试验/NCT00603291
NCT00603291已完成3 期

A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Overweight and Obese Patients With Type 2 Diabetes Mellitus Managed With Oral Hypoglycemic Agent(s)

Eisai Inc.1 个研究点 分布在 1 个国家目标入组 604 人开始时间: 2007年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Eisai Inc.
入组人数
604
试验地点
1
主要终点
Co-primary Endpoint- Percentage of Participants Achieving Greater Than or Equal to 5% Weight Loss From Baseline to Week 52

研究概览

简要总结

The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients with Type II diabetes mellitus treated with metformin, sulfonylurea (SFU), or either agent in combination with other oral hypoglycemic agents.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Overweight/obese men and women with type 2 diabetes mellitus that is managed with oral anti-hyperglycemic agent(s).
  • Body mass index (BMI) 27 to 45 kg/m2, inclusive.
  • Ability to complete a 1 year study

排除标准

  • Pregnancy
  • Use of insulin in any form, exenatide (Byetta) or pramlintide (Symlin) within 3 months prior to screening
  • History of symptomatic heart valve disease
  • Serious or unstable current or past medical conditions

研究组 & 干预措施

Lorcaserin 10 mg BID

Experimental

Lorcaserin 10 mg tablet each morning and evening

干预措施: Lorcaserin 10 mg twice a day (BID) (Drug)

Lorcaserin 10 mg QD

Experimental

Lorcaserin 10 mg tablet each morning and placebo tablet each evening

干预措施: Lorcaserin 10 mg once daily (QD) (Drug)

Matching Placebo

Placebo Comparator

Matching placebo tablet each morning and evening

干预措施: Matching Placebo (Drug)

结局指标

主要结局

Co-primary Endpoint- Percentage of Participants Achieving Greater Than or Equal to 5% Weight Loss From Baseline to Week 52

时间窗: Baseline and Week 52

The percentage of patients with a reduction from baseline body weight of 5% or more after 52 weeks.

次要结局

  • Percent Change in Body Weight From Baseline to Week 52(Baseline and Week 52)

研究者

发起方
Eisai Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验